Metals and oxidative stress in patients with Parkinson's disease

Annali dell'Istituto Superiore di Sanita

Volumn 41, Issue 2, 2005, Pages 189-195

  Forte, Giovanni ^a   Alimonti, Alessandro ^a,d   Pino, Anna ^a   Stanzione, Paolo ^b   Brescianini, Sonia ^a   Brusa, Livia ^c   Sancesario, Giuseppe ^b   Violante, Nicola ^a   Bocca, Beatrice ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c S Eugenia Hospital   (Italy)

^d Dipartimento di Ambiente e Connessa Prevenzione Primaria   (United States)

Author keywords

Blood; Metals; Oxidative status; Parkinson's disease; Serum

Indexed keywords

ALPHA SYNUCLEIN; ALUMINUM; ANTIMONY; BARIUM; BERYLLIUM; BIOLOGICAL MARKER; BISMUTH; CADMIUM; CALCIUM; CHROMIUM; COBALT; COPPER; IRON; LEAD; LITHIUM; MAGNESIUM; MANGANESE; MERCURY; METAL; MOLYBDENUM; NICKEL; SILICON; STRONTIUM; THALLIUM; TIN; TUNGSTEN; UNINDEXED DRUG; VANADIUM; ZINC; ZIRCONIUM;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; SERUM;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METALS; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SILICON;

EID: 31644442799     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson's disease. J Neurol Sci 2004;217:169-74.
2. Youdim MB, Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J Neural Transm Suppl 1993;40:57-67.
3. Gerlach M, Ben Shachar D, Riederer P, Youdim BH. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 1994;63:793-807.
4. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-6.
5. Kienzl E, Jellinger K, Stachelberger H, Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease. Life Sci 1999;65:1973-6.
6. Takeda A. Manganese action in brain function. Brain Res Rev 2003;41:79-87.
7. Aschner M. Manganese: brain transport and emerging research needs. Environ Health Persp 2000;108(Suppl. 3):429-32.
8. Johnson S. Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease? Med Hypotheses 2001;56:641-5.
9. Rossi L, Lombarde MF, Ciriolo MR, Rotilio G. Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res 2004;29:493-504.
10. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994;7:548-58.
11. Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminium concentrations in Parkinson's disease. Neurotoxicology 1992; 13:593-600.
12. Click JL. Use of magnesium in the management of dementias. Med Sci Res 1990;18:831-3.
13. Platen TP. Geographical associations between aluminium in drinking water and death rates with dementia, Parkinson's disease and amyotrophic lateral sclerosis in Norway. Trace Elem Med 1987;4:179-80.
14. Gutteridge JMC, Quinlan GJ, Clark IA, Halliwell B. Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 1985;35:441-7.
15. Birchall JD, Chappell JS. The chemistry of aluminium and silicon in relation to Alzheimer's disease. Clin Chem 1988; 34:265-7.
16. McLachlan D. Aluminium and the risk for Alzheimer's disease. Environmetrics 1995;6:233-75.
17. Pamphlett R, Waley P. Mercury in human spinal motor neuron. Acta Neuropathol 1998;96:515-9.
18. Chavez E, Holguin JA. Mitochondrial calcium release as induced by Hg. J Biol Chem 1988;263:3582-7.
19. Ngim C-H, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-41.
20. Lucchini R, Albini E, Cortesi I, Placidi D, Bergamaschi E, Traversa F, Alessio L. Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure. Neurotoxicology 2000;21:805-12.
21. Uversky VN, Li J, Bower K, Fink AL. Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: Implications for Parkinson's disease. Neurotoxicology 2002; 23:527-36.
22. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of α-synuclein. J Biol Chem 2002;277:16116-23.
23. Daniel SE, Lees AJ. Parkinson's disease society brain bank, London: overview and research. J Neural Transm 1993;39:165-72.
24. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
25. Bocca B, Alimonti A, Petrucci F, Senofonte O, Violante N, Forte G. Development of methods for the quantification of essential and toxic elements in human biomonitoring. Ann 1st Super Sanità 2005;41(2): (questo numero)
26. Jiménez-Jiménez FJ, Molina JA, Aguilar MV, Arrieta FJ, Jorge-Santamaría A, Cabrera-Valdivia F, Ayuso-Peralta L, Rabasa M, Vázquez A, García-Albea E, Martínez-Para MC. Serum and urinary manganese levels in patients with Parkinson's disease. Acta Neurol Scand 1995;91:317-20.
27. Hegde LM, Shanmugavelu P, Vengamma B, Sathyanarayana Rao TS, Menon RB, Rao RV, Jagannatha Rao KS. Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease. J Trace Elem Med Biol 2004;18:163-71.
28. Pamphlett R, McQuilty R, Zarkos K. Blood levels of toxic and essential metals in motor neuron disease. Neurotoxicology 2001;22:401-10.
29. Jiménez-Jiménez FJ, Fernández-Calle P, Martínez-Vanaclocha M, Herrero E, Molina JA, Vásquez A, Codoceo R. Serum levels of zinc and copper in patients with Parkinson's disease. J Neurol Sci 1992;112:30-3.
30. Kocatürk PA, Akbostanaci MC, Tan F, Kavas GÖ. Superoxide dismutase activity and zinc and copper concentrations in Parkinson's disease. Pathophysiology 2000;7:63-7.
31. Okuda B, Iwamoto Y, Tachibana H, Sugita M, Parkinsonism after acute cadmium poisoning, Clin Neurol Neurosurg 1997;99:263-5.
32. Logroscino G, Karder K, Graziano J, Freyer G, Slavkovich V, Lolacono N, Cote L, Mayeux R. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997:49; 714-7.
33. Cabrera-Valdivia F, Jiménez-Jiménez FJ, Molina JA, Férnandez-Calle P, Vázquez A, Cañizares-Liébana F, Larumbe-Lobalde S, Ayuso-Peralta L, Rabasa M, Codoceo R. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci 1994;125:82-6.
34. Tórsdóttir G, Kristinsson J, Svéinbjö rnsdóttir S, Snaedal J, Jóhannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999;85:239-43.